Patents Represented by Attorney Dechert LLP
  • Patent number: 8349330
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: January 8, 2013
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Patent number: 8349842
    Abstract: Piperidine Compounds; compositions comprising a Piperidine Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperidine Compound are disclosed. In one embodiment, the Piperidine Compound has the formula: and pharmaceutically acceptable salts thereof, wherein Ar1, Ar2, X, R3, R4, and m are as disclosed herein.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: January 8, 2013
    Assignee: Purdue Pharma, L.P.
    Inventors: Qun Sun, Kate Xin Wen, Xiaoming Zhou
  • Patent number: 8337836
    Abstract: Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of endogenous elastase and collagenase in the wall of the conduit, either by cells that are normally present in the wall of the conduit or by inflammatory cells that are attracted to the conduit, thereby providing additional conduit dilation. Methods also include the use of agents that increase conduit wall permeability and expose elastin and collagen fibers. Methods also include removing components of the extracellular matrix of arteries and veins leading to an inhibition of intimal hyperplasia in the wall of the vessels by decreasing biomechanical stimuli directed toward the cells in the wall of the vessel. Methods further include the use of agent that degrade microfibers, in addition to elastin, in order to decrease the resynthesis of elastin.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: December 25, 2012
    Assignee: Proteon Therapeutics, Inc.
    Inventor: F. Nicholas Franano
  • Patent number: 8324252
    Abstract: This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: December 4, 2012
    Assignee: Astrazeneca AB
    Inventors: Audrey Davies, Michelle Lamb, Paul Lyne, Tao Wang, Dingwei Yu, Peter Mohr, Bin Wang
  • Patent number: 8298525
    Abstract: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: October 30, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Roland Martin, Henry McFarland, Bibiana Bielekova, Thomas Waldmann
  • Patent number: 8283380
    Abstract: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 9, 2012
    Assignee: Newron Pharmaceuticals S.p.A.
    Inventors: Ruggero Fariello, Carlo Cattaneo, Patricia Salvati, Luca Benatti
  • Patent number: 8278485
    Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: October 2, 2012
    Assignee: Newron Pharmaceuticals S.p.A.
    Inventors: Elena Barbanti, Carla Caccia, Patricia Salvati, Francesco Velardi, Tiziano Ruffilli, Luigi Bogogna
  • Patent number: 8211466
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: July 3, 2012
    Assignee: Bioalliance Pharma
    Inventors: Dominique Costantini, Caroline Lemarchand
  • Patent number: 8206750
    Abstract: The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: June 26, 2012
    Assignee: Cerenis Therapeutics Holding S.A.
    Inventor: Jean-Louis Dasseux
  • Patent number: 8198444
    Abstract: Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of formula R1SR2 and a base. In one embodiment, the alcohol is a compound of formula (I): wherein R3 is a protecting group. Also disclosed are methods for making 3-O-protected morphine dienol carboxylates comprising allowing a compound of formula (I) to oxidize in the presence of a chlorine-containing compound and a compound of formula R1SR2; and allowing the product of the oxidation step to react with an acylating agent.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: June 12, 2012
    Assignee: Purdue Pharma L.P.
    Inventor: Andreas Stumpf
  • Patent number: 8133981
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 13, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Patent number: 8129427
    Abstract: 2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: March 6, 2012
    Assignee: Newron Pharmaceuticals S.p.A.
    Inventors: Florian Thaler, Mauro Napoletano, Cibele Sabido-David, Ermanno Moriggi, Carla Caccia, Laura Faravelli, Alessandra Restivo, Patricia Salvati
  • Patent number: 8129388
    Abstract: The present invention discloses compounds of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Phenylene Compound”); compositions comprising an effective amount of a Phenylene Compound; and methods for treating pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Phenylene Compound.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: March 6, 2012
    Assignee: Purde Pharma L.P.
    Inventor: Qun Sun
  • Patent number: 8128924
    Abstract: The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelialization and angiogenesis in the heart and related tissues. The three-dimensional stromal tissue of the present invention may be used in a variety of applications including, but not limited to, promoting repair of and regeneration of damaged cardiac muscle, promoting vascularization and healing during cardiac surgery, promoting blood vessel formation at anastomosis sites, and promoting vascularization and repair of damaged skeletal muscle, smooth muscle or connective tissue.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: March 6, 2012
    Assignee: Theregen, Inc.
    Inventors: Gail K. Naughton, Jonathan Noel Mansbridge, Robert Emmett Pinney, Joan Zeltinger
  • Patent number: 8110602
    Abstract: The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: February 7, 2012
    Assignee: Purdue Pharma L.P.
    Inventors: Kevin C. Brown, R. Richard Goehring, Yoshiyasu Baba, Naoki Tsuno
  • Patent number: 8100067
    Abstract: The invention pertains to apparatus and methods for injecting viscous fertilizer, such as dewatered biosolids, below the surface of the soil. The invention also pertains to apparatus and methods for creating a continuous flow of viscous material and for dividing a flow of viscous material.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: January 24, 2012
    Assignee: American Water Works Company, Inc.
    Inventors: Phil Sidhwa, Dan Goldhawk, Walter Stewart Grose, Gordon Raymond Grose
  • Patent number: 8088898
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: January 3, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Patent number: 8084447
    Abstract: There is disclosed a pharmaceutical composition comprising gabapentin or an analogue thereof (pregabalin or tiagabine) and an ?-aminoamide and its analgesic use. A synergistic effect of the respective analgesic activities without concomitant increase of side effects was observed.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: December 27, 2011
    Assignee: Newron Pharmaceuticals S.p.A.
    Inventors: Patricia Salvati, Orietta Veneroni, Roberto Maj, Ruggero Fariello, Luca Benatti
  • Patent number: 8084612
    Abstract: The invention relates to compounds of Formulae I(a) to XI and pharmaceutically acceptable salts and solvates thereof (Proline Analog Compounds), that are useful, e.g., as ligands for cannabinoid receptors, as compositions comprising a Proline Analog Compound and a pharmaceutically acceptable carrier, in methods of making such Proline Analog Compounds, and in methods for treating or preventing a Condition, such as pain, nausea, vomiting and an eating disorder, comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: December 27, 2011
    Assignee: Purdue Pharma L.P.
    Inventors: Bin Shao, Jiangchao Yao
  • Patent number: 8076515
    Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: December 13, 2011
    Assignee: Newron Pharmaceuticals S.p.A.
    Inventors: Elena Barbanti, Carla Caccia, Patricia Salvati, Francesco Velardi, Tiziano Ruffilli, Luigi Bogogna